Mammograms & Breast Health:
The Questions Nobody Asked You

Every year, millions of women schedule a mammogram because they were told it could save their life. And that may be true — for some women, in some circumstances. But there is a conversation that almost never happens before that mammogram — about what finding something might actually mean. About what a recall involves. About how often the cancer found was never going to cause harm.

This is not a video telling you to skip your mammogram. This is a video giving you what you need to make an actual informed decision about it.

Let's start with the number that is almost never told to women at the point of scheduling. If you have an annual mammogram starting at age 40 and continue for ten years — following the current guidelines — your cumulative probability of receiving at least one false-positive result is 50 to 60 percent. That means: you will likely be called back, told something needs to be looked at again, put through additional imaging, possibly a biopsy — for a finding that turns out to be nothing.

Between 7 and 12 percent of women will have a biopsy over that same ten-year period. A biopsy on breast tissue you didn't need because the mammogram flagged something benign. This is not a fringe concern. It is the documented outcome rate in the peer-reviewed literature, including studies cited by the American Cancer Society.

And then there's the experience of the recall itself — being told something was found, waiting for an appointment, the anxiety, the disrupted sleep. Research has documented that the psychological harm from a false-positive persists beyond the eventual all-clear. It is a real cost that is not on the consent form you signed.

Here is the harder conversation. Some of what mammography finds is a real cancer. A genuine, biopsy-confirmed cancer. But — a significant percentage of those cancers would never have gone on to cause harm. They would have remained dormant, or been resolved by the immune system, or grown so slowly they would have been outlived.

The Nordic Cochrane Centre — after conducting the most comprehensive review of every randomized controlled trial on mammography — concluded that for every one woman who has her life saved by screening, ten women are overdiagnosed and treated unnecessarily. That's mastectomy, radiation, chemotherapy, hormone suppression — for a cancer that was never going to kill them. The harm isn't hypothetical. Chemotherapy carries long-term cognitive effects. Radiation to the chest carries a documented risk of radiation-induced heart disease and secondary cancers. These are real costs borne by real women.

DCIS — ductal carcinoma in situ — is the diagnosis at the center of this. 60,000 American women per year are diagnosed with DCIS through screening. Many are treated aggressively. Long-term data now shows that the survival rate for DCIS treated conservatively versus aggressively is not meaningfully different. Which means many of those women went through major treatment they did not need.

Half of women have dense breast tissue. Dense breasts are not just harder to read on a mammogram — cancer is actively masked in them, because both dense glandular tissue and cancer appear white on the image. A woman with dense breasts can receive a normal mammogram and have a significant cancer that simply wasn't visible. Most women are never told their breast density. Most are not told that in their case, mammography is substantially less effective.

And then there is the radiation itself. Each mammogram delivers ionizing radiation — radiation that can damage DNA — directly to breast tissue. The dose from any single mammogram is low. The question is cumulative: forty years of annual screening, plus additional views for dense tissue, plus follow-up imaging after false positives. The long-term data on cumulative mammographic radiation and breast cancer risk is not resolved.

Mammography is not the only option. Breast ultrasound works without radiation and performs better in dense tissue. MRI has the highest sensitivity of all modalities but comes with gadolinium contrast agent use, a very high false-positive rate, and significant cost. Thermal imaging — which detects heat and blood vessel patterns before a mass is detectable on structural imaging — is available and provides information mammography cannot.

These options are rarely discussed at the point of scheduling a standard mammogram. Discussing them with your clinician is not anti-medicine — it is asking for the full picture of what is available to you.

Breast cancer risk is not fixed. Estrogen dominance — relative excess of estrogen to progesterone — is one of the most consistent risk factors, and it is modifiable. Reducing xenoestrogens from plastics, personal care products, and alcohol. Supporting hepatic estrogen clearance. Understanding which herbs and supplements interact with your hormone receptors. Sunlight exposure for vitamin D from the skin — not supplemental isolated vitamin D. Sleep in darkness for melatonin's oncostatic effects.

The Frajese 2018 study found that electrochemically reduced water inhibited breast cancer cell survival and slowed mammary tumor growth in preclinical models — through mechanisms involving ErbB2/neu expression and AKT signaling. The research is early. The biological mechanism is real. It's one more reason that how you hydrate matters.

What we are asking for is not a boycott of screening. We are asking for the conversation that should have happened before you walked into the imaging center. The questions you need are in the written article below. The studies are in the Resources tab. You are entitled to the full picture — including the parts the scheduling nurse didn't mention.